Chrexanthomycin A Targets Neurodegenerative Disease Pathways

The patent applies multi-functionality by designing a single compound that simultaneously targets multiple pathological pathways in neurodegenerative diseases. The compound exhibits dual mechanisms: (1) binding to G-quadruplex DNA/RNA structures to reduce excitotoxicity and RNA foci toxicity, and (2) scavenging reactive oxygen species. This multi-functional approach allows one drug to address multiple disease mechanisms concurrently, transitioning from traditional single-target therapy to multi-pathway intervention.

The patent employs a composite therapeutic strategy by combining multiple therapeutic mechanisms within a single molecular framework. The compound integrates G-quadruplex binding activity and antioxidant scavenging capability, creating a composite therapeutic agent that addresses both excitotoxicity/RNA foci pathways and oxidative stress pathways simultaneously. This composite approach enhances therapeutic reliability by covering multiple disease progression mechanisms.

The patent applies preliminary action by preventing pathological changes before they lead to neuronal death and irreversible damage. The compound proactively binds to G-quadruplex structures to prevent excitotoxicity and scavenges reactive oxygen species before they cause oxidative damage. This preventive mechanism addresses the root causes of disease progression rather than merely compensating for dopamine deficiency, providing sustained therapeutic effect throughout disease progression.

The patent converts harmful pathological structures into beneficial targets by specifically binding to G-quadruplex DNA and RNA structures that are normally involved in gene regulation but become pathogenic in ALS. By targeting these G4 structures, the compound transforms the pathological excitotoxicity mechanism into a treatable target, while simultaneously converting the harmful oxidative stress into a target for scavenging, thereby preventing disease progression.